High-density lipoprotein remodeling by phospholipid nanoparticles improves cholesterol efflux capacity and protects from atherosclerosis

The efficiency of cholesterol efflux from cells promoted by high-density lipoproteins (HDLs) depends on HDL concentration and functional properties. The term “dysfunctional HDL” describes HDLs with impaired protective properties. Cholesterol efflux capacity (CEC) of HDL is reduced in patients with a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biomedicine & pharmacotherapy 2021-09, Vol.141, p.111900-111900, Article 111900
Hauptverfasser: Kudinov, Vasily A., Torkhovskaya, Tatiana I., Zakharova, Tamara S., Morozevich, Galina E., Artyushev, Rafael I., Zubareva, Marina Yu, Markin, Sergey S.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 111900
container_issue
container_start_page 111900
container_title Biomedicine & pharmacotherapy
container_volume 141
creator Kudinov, Vasily A.
Torkhovskaya, Tatiana I.
Zakharova, Tamara S.
Morozevich, Galina E.
Artyushev, Rafael I.
Zubareva, Marina Yu
Markin, Sergey S.
description The efficiency of cholesterol efflux from cells promoted by high-density lipoproteins (HDLs) depends on HDL concentration and functional properties. The term “dysfunctional HDL” describes HDLs with impaired protective properties. Cholesterol efflux capacity (CEC) of HDL is reduced in patients with atherosclerosis, but the exact mechanisms underlying this impairment are not well characterized. Enriching HDLs with phospholipids (PLs) improves CEC. Herein, we assessed the potential of PL nanoparticles in improving HDL functionality. We lipidated HDL subfractions by incubating with PL nanoparticles containing soybean polyunsaturated phosphatidylcholine. Incubating blood plasma with PL nanoparticles resulted in the dose-dependent lipidation of all HDL subfractions. Changes in apolipoprotein A1 (apoA-1) and PL concentrations were the most prominent in the HDL2 fraction. Concentrations of PL in the HDL3 fraction and the fraction with a density > 1.21 g/mL increased by 30–50%, whereas apoA-1 levels decreased. We hypothesized that PL nanoparticles may cause HDL remodeling that can improve their functions. The CECs of lipidated HDLs were analyzed by incubating apolipoprotein B (apoB)-depleted plasma with 3H-cholesterol-labeled THP-1 macrophages. The findings revealed a two-fold increase in cholesterol efflux compared with native apoB-depleted plasma. Moreover, intravenous administration of PL nanoparticles restored lipid profiles and effectively protected blood vessels from atherosclerosis progression in cholesterol-fed rabbits compared with that of fenofibrate and atorvastatin. PL nanoparticles also protected against atherosclerosis and decreased the atherogenic index. Altogether, these results indicate that PL nanoparticles can be used to correct the lipid composition and CEC of HDLs. Additional data can be provided upon reasonable request from the date of publication of this article within 5 years. The request should be sent to the author-correspondent at the address cd95@mail.ru. [Display omitted] •Ultra-small phospholipid nanoparticles based on soybean PC were synthesized.•Phospholipid nanoparticles effectively lipidated HDL.•Lipidation leads to the remodeling of HDL subfractions.•Uptake of radiolabeled cholesterol from THP-1 macrophages increased > 2-fold.•Our findings may be used as a new strategy to improve impaired HDL functions.
doi_str_mv 10.1016/j.biopha.2021.111900
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2557232853</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S075333222100682X</els_id><sourcerecordid>2557232853</sourcerecordid><originalsourceid>FETCH-LOGICAL-c408t-79c5e0f86be5f490b6d118a84fdb5d1984934e6985a0d2c9dcdab397735618573</originalsourceid><addsrcrecordid>eNp9UcuO1DAQtBCIHRb-ACEfuWRox3FiX5DQCliklbjA2XLszo5HSRzszIr5Az6bHrJw5OCH5KrqchVjrwXsBYj23XHfx7Qc3L6GWuyFEAbgCdsJo6BqAbqnbAedkpWUdX3FXpRyBADVSv2cXclG1loA7Niv23h_qALOJa5nPsYlLTmtGGeecUoBxzjf8_7Ml0MqtAgQA5_dnBaX1-hHLDxORHmgi6d3LCvmNHIchvH0k3u3OH9RdnPgf5T9WviQ08TdeiBkIQnaY3nJng1uLPjq8bxm3z99_HZzW919_fzl5sNd5RvQa9UZrxAG3faohsZA3wYhtNPNEHoVhNGNkQ22RisHofYm-OB6abpOqlZo1clr9nbTJTc_TmTXTrF4HEc3YzoVWyvV1ZSOkgRtNqgnhyXjYJccJ5fPVoC9dGCPduvAXjqwWwdEe_M44dRPGP6R_oZOgPcbAOmfDxGzLT7i7DHETPnYkOL_J_wGI3Sdvw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2557232853</pqid></control><display><type>article</type><title>High-density lipoprotein remodeling by phospholipid nanoparticles improves cholesterol efflux capacity and protects from atherosclerosis</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Kudinov, Vasily A. ; Torkhovskaya, Tatiana I. ; Zakharova, Tamara S. ; Morozevich, Galina E. ; Artyushev, Rafael I. ; Zubareva, Marina Yu ; Markin, Sergey S.</creator><creatorcontrib>Kudinov, Vasily A. ; Torkhovskaya, Tatiana I. ; Zakharova, Tamara S. ; Morozevich, Galina E. ; Artyushev, Rafael I. ; Zubareva, Marina Yu ; Markin, Sergey S.</creatorcontrib><description>The efficiency of cholesterol efflux from cells promoted by high-density lipoproteins (HDLs) depends on HDL concentration and functional properties. The term “dysfunctional HDL” describes HDLs with impaired protective properties. Cholesterol efflux capacity (CEC) of HDL is reduced in patients with atherosclerosis, but the exact mechanisms underlying this impairment are not well characterized. Enriching HDLs with phospholipids (PLs) improves CEC. Herein, we assessed the potential of PL nanoparticles in improving HDL functionality. We lipidated HDL subfractions by incubating with PL nanoparticles containing soybean polyunsaturated phosphatidylcholine. Incubating blood plasma with PL nanoparticles resulted in the dose-dependent lipidation of all HDL subfractions. Changes in apolipoprotein A1 (apoA-1) and PL concentrations were the most prominent in the HDL2 fraction. Concentrations of PL in the HDL3 fraction and the fraction with a density &gt; 1.21 g/mL increased by 30–50%, whereas apoA-1 levels decreased. We hypothesized that PL nanoparticles may cause HDL remodeling that can improve their functions. The CECs of lipidated HDLs were analyzed by incubating apolipoprotein B (apoB)-depleted plasma with 3H-cholesterol-labeled THP-1 macrophages. The findings revealed a two-fold increase in cholesterol efflux compared with native apoB-depleted plasma. Moreover, intravenous administration of PL nanoparticles restored lipid profiles and effectively protected blood vessels from atherosclerosis progression in cholesterol-fed rabbits compared with that of fenofibrate and atorvastatin. PL nanoparticles also protected against atherosclerosis and decreased the atherogenic index. Altogether, these results indicate that PL nanoparticles can be used to correct the lipid composition and CEC of HDLs. Additional data can be provided upon reasonable request from the date of publication of this article within 5 years. The request should be sent to the author-correspondent at the address cd95@mail.ru. [Display omitted] •Ultra-small phospholipid nanoparticles based on soybean PC were synthesized.•Phospholipid nanoparticles effectively lipidated HDL.•Lipidation leads to the remodeling of HDL subfractions.•Uptake of radiolabeled cholesterol from THP-1 macrophages increased &gt; 2-fold.•Our findings may be used as a new strategy to improve impaired HDL functions.</description><identifier>ISSN: 0753-3322</identifier><identifier>EISSN: 1950-6007</identifier><identifier>DOI: 10.1016/j.biopha.2021.111900</identifier><identifier>PMID: 34328100</identifier><language>eng</language><publisher>France: Elsevier Masson SAS</publisher><subject>Animals ; Apolipoprotein A-I - metabolism ; Apolipoproteins B - blood ; Atherosclerosis - blood ; Atherosclerosis - prevention &amp; control ; Atorvastatin ; Chinchilla ; Cholesterol ; Cholesterol - blood ; Cholesterol - metabolism ; Cholesterol, Dietary ; Disease Progression ; Dose-Response Relationship, Drug ; Dyslipidemia ; Humans ; Lipoproteins, HDL - drug effects ; Macrophage ; Macrophages - metabolism ; Male ; Nanoparticles ; Phosphatidylcholine ; Phosphatidylcholines - pharmacology ; Phospholipids - pharmacology ; Rabbits ; Reverse cholesterol transport</subject><ispartof>Biomedicine &amp; pharmacotherapy, 2021-09, Vol.141, p.111900-111900, Article 111900</ispartof><rights>2021 The Authors</rights><rights>Copyright © 2021 The Authors. Published by Elsevier Masson SAS.. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c408t-79c5e0f86be5f490b6d118a84fdb5d1984934e6985a0d2c9dcdab397735618573</citedby><cites>FETCH-LOGICAL-c408t-79c5e0f86be5f490b6d118a84fdb5d1984934e6985a0d2c9dcdab397735618573</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S075333222100682X$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34328100$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kudinov, Vasily A.</creatorcontrib><creatorcontrib>Torkhovskaya, Tatiana I.</creatorcontrib><creatorcontrib>Zakharova, Tamara S.</creatorcontrib><creatorcontrib>Morozevich, Galina E.</creatorcontrib><creatorcontrib>Artyushev, Rafael I.</creatorcontrib><creatorcontrib>Zubareva, Marina Yu</creatorcontrib><creatorcontrib>Markin, Sergey S.</creatorcontrib><title>High-density lipoprotein remodeling by phospholipid nanoparticles improves cholesterol efflux capacity and protects from atherosclerosis</title><title>Biomedicine &amp; pharmacotherapy</title><addtitle>Biomed Pharmacother</addtitle><description>The efficiency of cholesterol efflux from cells promoted by high-density lipoproteins (HDLs) depends on HDL concentration and functional properties. The term “dysfunctional HDL” describes HDLs with impaired protective properties. Cholesterol efflux capacity (CEC) of HDL is reduced in patients with atherosclerosis, but the exact mechanisms underlying this impairment are not well characterized. Enriching HDLs with phospholipids (PLs) improves CEC. Herein, we assessed the potential of PL nanoparticles in improving HDL functionality. We lipidated HDL subfractions by incubating with PL nanoparticles containing soybean polyunsaturated phosphatidylcholine. Incubating blood plasma with PL nanoparticles resulted in the dose-dependent lipidation of all HDL subfractions. Changes in apolipoprotein A1 (apoA-1) and PL concentrations were the most prominent in the HDL2 fraction. Concentrations of PL in the HDL3 fraction and the fraction with a density &gt; 1.21 g/mL increased by 30–50%, whereas apoA-1 levels decreased. We hypothesized that PL nanoparticles may cause HDL remodeling that can improve their functions. The CECs of lipidated HDLs were analyzed by incubating apolipoprotein B (apoB)-depleted plasma with 3H-cholesterol-labeled THP-1 macrophages. The findings revealed a two-fold increase in cholesterol efflux compared with native apoB-depleted plasma. Moreover, intravenous administration of PL nanoparticles restored lipid profiles and effectively protected blood vessels from atherosclerosis progression in cholesterol-fed rabbits compared with that of fenofibrate and atorvastatin. PL nanoparticles also protected against atherosclerosis and decreased the atherogenic index. Altogether, these results indicate that PL nanoparticles can be used to correct the lipid composition and CEC of HDLs. Additional data can be provided upon reasonable request from the date of publication of this article within 5 years. The request should be sent to the author-correspondent at the address cd95@mail.ru. [Display omitted] •Ultra-small phospholipid nanoparticles based on soybean PC were synthesized.•Phospholipid nanoparticles effectively lipidated HDL.•Lipidation leads to the remodeling of HDL subfractions.•Uptake of radiolabeled cholesterol from THP-1 macrophages increased &gt; 2-fold.•Our findings may be used as a new strategy to improve impaired HDL functions.</description><subject>Animals</subject><subject>Apolipoprotein A-I - metabolism</subject><subject>Apolipoproteins B - blood</subject><subject>Atherosclerosis - blood</subject><subject>Atherosclerosis - prevention &amp; control</subject><subject>Atorvastatin</subject><subject>Chinchilla</subject><subject>Cholesterol</subject><subject>Cholesterol - blood</subject><subject>Cholesterol - metabolism</subject><subject>Cholesterol, Dietary</subject><subject>Disease Progression</subject><subject>Dose-Response Relationship, Drug</subject><subject>Dyslipidemia</subject><subject>Humans</subject><subject>Lipoproteins, HDL - drug effects</subject><subject>Macrophage</subject><subject>Macrophages - metabolism</subject><subject>Male</subject><subject>Nanoparticles</subject><subject>Phosphatidylcholine</subject><subject>Phosphatidylcholines - pharmacology</subject><subject>Phospholipids - pharmacology</subject><subject>Rabbits</subject><subject>Reverse cholesterol transport</subject><issn>0753-3322</issn><issn>1950-6007</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UcuO1DAQtBCIHRb-ACEfuWRox3FiX5DQCliklbjA2XLszo5HSRzszIr5Az6bHrJw5OCH5KrqchVjrwXsBYj23XHfx7Qc3L6GWuyFEAbgCdsJo6BqAbqnbAedkpWUdX3FXpRyBADVSv2cXclG1loA7Niv23h_qALOJa5nPsYlLTmtGGeecUoBxzjf8_7Ml0MqtAgQA5_dnBaX1-hHLDxORHmgi6d3LCvmNHIchvH0k3u3OH9RdnPgf5T9WviQ08TdeiBkIQnaY3nJng1uLPjq8bxm3z99_HZzW919_fzl5sNd5RvQa9UZrxAG3faohsZA3wYhtNPNEHoVhNGNkQ22RisHofYm-OB6abpOqlZo1clr9nbTJTc_TmTXTrF4HEc3YzoVWyvV1ZSOkgRtNqgnhyXjYJccJ5fPVoC9dGCPduvAXjqwWwdEe_M44dRPGP6R_oZOgPcbAOmfDxGzLT7i7DHETPnYkOL_J_wGI3Sdvw</recordid><startdate>202109</startdate><enddate>202109</enddate><creator>Kudinov, Vasily A.</creator><creator>Torkhovskaya, Tatiana I.</creator><creator>Zakharova, Tamara S.</creator><creator>Morozevich, Galina E.</creator><creator>Artyushev, Rafael I.</creator><creator>Zubareva, Marina Yu</creator><creator>Markin, Sergey S.</creator><general>Elsevier Masson SAS</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202109</creationdate><title>High-density lipoprotein remodeling by phospholipid nanoparticles improves cholesterol efflux capacity and protects from atherosclerosis</title><author>Kudinov, Vasily A. ; Torkhovskaya, Tatiana I. ; Zakharova, Tamara S. ; Morozevich, Galina E. ; Artyushev, Rafael I. ; Zubareva, Marina Yu ; Markin, Sergey S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c408t-79c5e0f86be5f490b6d118a84fdb5d1984934e6985a0d2c9dcdab397735618573</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Animals</topic><topic>Apolipoprotein A-I - metabolism</topic><topic>Apolipoproteins B - blood</topic><topic>Atherosclerosis - blood</topic><topic>Atherosclerosis - prevention &amp; control</topic><topic>Atorvastatin</topic><topic>Chinchilla</topic><topic>Cholesterol</topic><topic>Cholesterol - blood</topic><topic>Cholesterol - metabolism</topic><topic>Cholesterol, Dietary</topic><topic>Disease Progression</topic><topic>Dose-Response Relationship, Drug</topic><topic>Dyslipidemia</topic><topic>Humans</topic><topic>Lipoproteins, HDL - drug effects</topic><topic>Macrophage</topic><topic>Macrophages - metabolism</topic><topic>Male</topic><topic>Nanoparticles</topic><topic>Phosphatidylcholine</topic><topic>Phosphatidylcholines - pharmacology</topic><topic>Phospholipids - pharmacology</topic><topic>Rabbits</topic><topic>Reverse cholesterol transport</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kudinov, Vasily A.</creatorcontrib><creatorcontrib>Torkhovskaya, Tatiana I.</creatorcontrib><creatorcontrib>Zakharova, Tamara S.</creatorcontrib><creatorcontrib>Morozevich, Galina E.</creatorcontrib><creatorcontrib>Artyushev, Rafael I.</creatorcontrib><creatorcontrib>Zubareva, Marina Yu</creatorcontrib><creatorcontrib>Markin, Sergey S.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Biomedicine &amp; pharmacotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kudinov, Vasily A.</au><au>Torkhovskaya, Tatiana I.</au><au>Zakharova, Tamara S.</au><au>Morozevich, Galina E.</au><au>Artyushev, Rafael I.</au><au>Zubareva, Marina Yu</au><au>Markin, Sergey S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>High-density lipoprotein remodeling by phospholipid nanoparticles improves cholesterol efflux capacity and protects from atherosclerosis</atitle><jtitle>Biomedicine &amp; pharmacotherapy</jtitle><addtitle>Biomed Pharmacother</addtitle><date>2021-09</date><risdate>2021</risdate><volume>141</volume><spage>111900</spage><epage>111900</epage><pages>111900-111900</pages><artnum>111900</artnum><issn>0753-3322</issn><eissn>1950-6007</eissn><abstract>The efficiency of cholesterol efflux from cells promoted by high-density lipoproteins (HDLs) depends on HDL concentration and functional properties. The term “dysfunctional HDL” describes HDLs with impaired protective properties. Cholesterol efflux capacity (CEC) of HDL is reduced in patients with atherosclerosis, but the exact mechanisms underlying this impairment are not well characterized. Enriching HDLs with phospholipids (PLs) improves CEC. Herein, we assessed the potential of PL nanoparticles in improving HDL functionality. We lipidated HDL subfractions by incubating with PL nanoparticles containing soybean polyunsaturated phosphatidylcholine. Incubating blood plasma with PL nanoparticles resulted in the dose-dependent lipidation of all HDL subfractions. Changes in apolipoprotein A1 (apoA-1) and PL concentrations were the most prominent in the HDL2 fraction. Concentrations of PL in the HDL3 fraction and the fraction with a density &gt; 1.21 g/mL increased by 30–50%, whereas apoA-1 levels decreased. We hypothesized that PL nanoparticles may cause HDL remodeling that can improve their functions. The CECs of lipidated HDLs were analyzed by incubating apolipoprotein B (apoB)-depleted plasma with 3H-cholesterol-labeled THP-1 macrophages. The findings revealed a two-fold increase in cholesterol efflux compared with native apoB-depleted plasma. Moreover, intravenous administration of PL nanoparticles restored lipid profiles and effectively protected blood vessels from atherosclerosis progression in cholesterol-fed rabbits compared with that of fenofibrate and atorvastatin. PL nanoparticles also protected against atherosclerosis and decreased the atherogenic index. Altogether, these results indicate that PL nanoparticles can be used to correct the lipid composition and CEC of HDLs. Additional data can be provided upon reasonable request from the date of publication of this article within 5 years. The request should be sent to the author-correspondent at the address cd95@mail.ru. [Display omitted] •Ultra-small phospholipid nanoparticles based on soybean PC were synthesized.•Phospholipid nanoparticles effectively lipidated HDL.•Lipidation leads to the remodeling of HDL subfractions.•Uptake of radiolabeled cholesterol from THP-1 macrophages increased &gt; 2-fold.•Our findings may be used as a new strategy to improve impaired HDL functions.</abstract><cop>France</cop><pub>Elsevier Masson SAS</pub><pmid>34328100</pmid><doi>10.1016/j.biopha.2021.111900</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0753-3322
ispartof Biomedicine & pharmacotherapy, 2021-09, Vol.141, p.111900-111900, Article 111900
issn 0753-3322
1950-6007
language eng
recordid cdi_proquest_miscellaneous_2557232853
source MEDLINE; Elsevier ScienceDirect Journals; EZB-FREE-00999 freely available EZB journals
subjects Animals
Apolipoprotein A-I - metabolism
Apolipoproteins B - blood
Atherosclerosis - blood
Atherosclerosis - prevention & control
Atorvastatin
Chinchilla
Cholesterol
Cholesterol - blood
Cholesterol - metabolism
Cholesterol, Dietary
Disease Progression
Dose-Response Relationship, Drug
Dyslipidemia
Humans
Lipoproteins, HDL - drug effects
Macrophage
Macrophages - metabolism
Male
Nanoparticles
Phosphatidylcholine
Phosphatidylcholines - pharmacology
Phospholipids - pharmacology
Rabbits
Reverse cholesterol transport
title High-density lipoprotein remodeling by phospholipid nanoparticles improves cholesterol efflux capacity and protects from atherosclerosis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T05%3A23%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=High-density%20lipoprotein%20remodeling%20by%20phospholipid%20nanoparticles%20improves%20cholesterol%20efflux%20capacity%20and%20protects%20from%20atherosclerosis&rft.jtitle=Biomedicine%20&%20pharmacotherapy&rft.au=Kudinov,%20Vasily%20A.&rft.date=2021-09&rft.volume=141&rft.spage=111900&rft.epage=111900&rft.pages=111900-111900&rft.artnum=111900&rft.issn=0753-3322&rft.eissn=1950-6007&rft_id=info:doi/10.1016/j.biopha.2021.111900&rft_dat=%3Cproquest_cross%3E2557232853%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2557232853&rft_id=info:pmid/34328100&rft_els_id=S075333222100682X&rfr_iscdi=true